Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a…

By C. Ryan, Matthew R. Smith, K. Fizazi, F. Saad, P. Mulders, C. Sternberg, K. Miller, C. Logothetis, N. Shore, E. Small and 15 more. The Lancet Oncology, 2015

1,271 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/336360edda4478a24e8721c734fd70713bac179c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Logothetis
2. T. Beer
3. Charles G. Drake
4. E. Kwon
5. F. Saad
6. G. Gravis
7. S. Ng
8. L. Sengeløv

Citations in the corpus

• Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (2017, neutral): “of patients reporting treatment after progression) 248 248 248 248 Any Docetaxel Abiraterone Enzalutamide (168) (83) (3) (5) 51 110 179 179 (21) (25) (3) (10) 21 58 122 116 (6) (5) (2) (8) 2 13 32 25 (1) (1) (0) (2) 18”
• Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017, background): “5 3 ULN 72 (18) 26 (13) Not reported 1 (, 1) 0 Gleason score # 7 189 (47) 103 (51) $ 8 192 (48) 91 (45) Not reported 19 (5) 8 (4) PSA Patients with available PSA data 393 197”
• Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer (2017, neutral): “Hypertension 219 (37) 121 (20) 0 133 (22) 59 (10) 1 (<1)”